453 Results

People

  1. Kelsen
    Kelsen
  2. Motzer
    Motzer
  3. Kris
    Kris
  4. Saltz
    Saltz
  5. Abrey
    Abrey
  6. O'Reilly
    O'Reilly
  7. Schwartz
    Schwartz
  8. Hudis
    Hudis
  9. Aghajanian
    Aghajanian
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (312)
  2. Solid Tumor Oncology Division (250)
  3. Survivorship Research (79)
  4. Gastrointestinal Oncology Service (76)
  5. Hematologic Malignancies, Division of (76)
  6. Radiology, Department of (64)
  7. Center for Hematologic Malignancies (63)
  8. Epidemiology and Biostatistics (61)
  9. Biostatistics Service (60)
  10. Genitourinary Oncology Service (59)
  1. "leukopenia"
Formats
  1. Journal Article (435)
  2. Review (9)
  3. Conference Paper (4)
  4. Editorial (2)
  5. Research Letter (2)
  6. Miscellaneous (1)
Groups
  1. Department of Medicine (312)
  2. Solid Tumor Oncology Division (250)
  3. Survivorship Research (79)
  4. Gastrointestinal Oncology Service (76)
  5. Hematologic Malignancies, Division of (76)
  6. Radiology, Department of (64)

More Groups

People
  1. David Kelsen (33)
  2. Robert Motzer (29)
  3. Mark Kris (25)
  4. Leonard Saltz (21)
  5. Eileen O'Reilly (18)
  6. Lauren Abrey (18)

More People

Years
  1. 2025 (10)
  2. 2024 (26)
  3. 2023 (9)
  4. 2022 (8)
  5. 2021 (6)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (42)
  2. Cancer (33)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (15)
  5. Gynecologic Oncology (14)
  6. Investigational New Drugs (14)

More Publications

Publishers
  1. Elsevier Inc. (68)
  2. Springer (52)
  3. American Society of Clinical Oncology (43)
  4. Wiley Blackwell (39)
  5. American Association for Cancer Research (36)
  6. Oxford University Press (33)

More Publishers

Results (453)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; Córdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of definitive radiotherapy vs. laryngectomy followed by adjuvant radiotherapy in patients with locally advanced laryngeal squamous cell carcinoma: Real-world experience in a referral cancer center
    Journal Article

    Kazemian, A.; Esmati, E.; Ghalehtaki, R.; Farazmand, B.; Mousavi-Darzikolaee, N.; Bayani, R.; Razmkhah, M.; Taherioun, M.; Saeedi, N.; Heidari, F.; more...
    Radiation Oncology (2024)

    Fulltext@MSK | Save
  • Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: The DELPHINUS study
    Journal Article

    Bhatla, T.; Hogan, L. E.; Teachey, D. T.; Bautista, F.; Moppett, J.; Velasco Puyó, P.; Micalizzi, C.; Rossig, C.; Shukla, N.; Gilad, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion Phase Ib trial
    Journal Article

    Hamilton, E. P.; Falchook, G. S.; Wang, J. S.; Fu, S.; Oza, A. M.; Imedio, E. R.; Kumar, S.; Ottesen, L.; Mugundu, G. M.; de Bruin, E. C.; more...
    Targeted Oncology (2024)

    Fulltext@MSK | Save
  • Best patient care practices for administering PSMA-targeted radiopharmaceutical therapy
    Review

    Calais, J.; Morris, M. J.; Kendi, A. T.; Kalebasty, A. R.; Tutrone, R.; Anderson, M. J.; Sartor, O.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial
    Journal Article

    Sun, L.; Xu, Y.; Chen, N.; Zhang, C.; Wu, A.; Wang, H.; Fei, Y.; Shu, P.; Diao, D.; Cheng, J.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma
    Journal Article

    Lochrin, S. E.; Cugliari, M. K.; Yeh, R.; Shoushtari, A. N.
    Melanoma Research (2024)

    Fulltext@MSK | Save
  • Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
    Journal Article

    Fontana, E.; Rosen, E.; Lee, E. K.; Højgaard, M.; Mettu, N. B.; Lheureux, S.; Carneiro, B. A.; Cote, G. M.; Carter, L.; Plummer, R.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
    Editorial

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
    Journal Article

    Yamashita, T.; Sohn, J. H.; Tokunaga, E.; Niikura, N.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Xu, B.; Wang, X.; Im, S. A.; more...
    Breast Cancer (2024)

    Fulltext@MSK | Save